{"id":792055,"date":"2024-12-03T11:03:57","date_gmt":"2024-12-03T16:03:57","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/former-merck-usa-president-joins-klotho-neurosciences-board-of-directors\/"},"modified":"2024-12-03T11:03:57","modified_gmt":"2024-12-03T16:03:57","slug":"former-merck-usa-president-joins-klotho-neurosciences-board-of-directors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/former-merck-usa-president-joins-klotho-neurosciences-board-of-directors\/","title":{"rendered":"Former Merck USA President Joins Klotho Neurosciences\u2019 Board of Directors"},"content":{"rendered":"

\nHighly Accomplished Pharmaceutical Leader, Riad El-Dada, Further Enhances Board Expertise
\n<\/h2>\n
\n

NEW YORK, Dec. 03, 2024 (GLOBE NEWSWIRE) — Klotho Neurosciences, Inc. (NASDAQ: KLTO<\/strong>), a U.S.-based biotechnology company pioneering cell and gene therapies for neurodegenerative and age-related disorders, including ALS, Alzheimer\u2019s, and Parkinson\u2019s, today announced the appointment of Riad El-Dada, former US President of Merck, to its Board of Directors.<\/p>\n

With decades of leadership in the pharmaceutical industry, Mr. El-Dada brings extensive experience in product development, commercialization, and strategic partnerships. During his tenure as US President of Merck, he oversaw commercial teams across a dozen therapeutic areas, managing over $12 billion in revenue. Prior to that role, he served as Managing Director for Merck\u2019s Australian and New Zealand operations.<\/p>\n

Mr. El-Dada\u2019s career is marked by impactful achievements, including negotiating key development and commercialization deals, as well as building collaborations across all phases of the pharmaceutical lifecycle. Before joining Merck, he advised Fortune 500 clients as a consultant with McKinsey & Company. He has also served on the Healthcare Leadership Council in Washington, DC, where he actively engaged with policymakers on Capitol Hill.<\/p>\n

Dr. Shalom Hirschman, Chair of the Board\u2019s Nominating Committee, commented: \u201cOn behalf of the Board, I am thrilled to welcome Riad El-Dada to Klotho Neurosciences. Riad\u2019s unparalleled expertise in pharmaceutical innovation, strategic leadership, and operational excellence will be invaluable as we advance our mission to develop groundbreaking therapies for neurodegenerative diseases. His proven track record of success positions him as a tremendous asset to Klotho Neurosciences as we accelerate the development of our patent-protected Klotho gene therapy, S-KL, aimed at addressing ALS, Alzheimer\u2019s, and Parkinson\u2019s. We are honored to have him join our Board.\u201d<\/p>\n

Expressing his enthusiasm, Mr. El-Dada stated: \u201cI am honored to join Klotho Neurosciences\u2019 Board of Directors. The company is developing potentially life-changing therapies using its innovative, patent-protected Klotho anti-aging gene, S-KL. I am eager to contribute to advancing Klotho\u2019s mission, helping realize its vision for transforming the treatment landscape for devastating diseases such as ALS, Alzheimer\u2019s, and Parkinson\u2019s. I look forward to playing my part on the Board where we aim to drive value for our shareholders and, most importantly, bring hope to millions of patients and families worldwide.\u201d<\/p>\n

\n About Klotho Neurosciences, Inc.<\/strong>\n <\/p>\n

Klotho Neurosciences, Inc. (NASDAQ: KLTO), is a biopharmaceutical company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the \u201canti-aging\u201d human Klotho gene (s-KL), and it\u2019s novel delivery system (s-KL\/AAV.myo) to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer’s, and Parkinson’s disease. The company\u2019s current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostics. Other assets include clinical-stage programs involving antibody biologics targeting cancer and autoimmune diseases, and drug delivery via a needle-free dry powder jet autoinjector called Nanoject. The company is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization.<\/p>\n

\n For more information, contact:
<\/strong>Eric Boyd
Investor Relations
Email: IR@klothoneuro.com<\/a>
<\/a>Website: www.klothoneuro.com<\/a><\/p>\n

\n Forward-Looking Statements:<\/strong>\n <\/p>\n

This press release contains forward-looking statements. These statements are made under the \u201csafe harbor\u201d provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words \u201cbelieve,\u201d \u201cproject,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cestimate,\u201d \u201cintend,\u201d \u201cstrategy,\u201d \u201cfuture,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cmay,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d \u201cwill be,\u201d \u201cwill continue,\u201d \u201cwill likely result,\u201d and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company\u2019s future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company\u2019s inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the \u201cSEC\u201d) from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. Copies of these documents are available on the SEC\u2019s website, www.sec.gov. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Highly Accomplished Pharmaceutical Leader, Riad El-Dada, Further Enhances Board Expertise NEW YORK, Dec. 03, 2024 (GLOBE NEWSWIRE) — Klotho Neurosciences, Inc. (NASDAQ: KLTO), a U.S.-based biotechnology company pioneering cell and gene therapies for neurodegenerative and age-related disorders, including ALS, Alzheimer\u2019s, and Parkinson\u2019s, today announced the appointment of Riad El-Dada, former US President of Merck, to its Board of Directors. With decades of leadership in the pharmaceutical industry, Mr. El-Dada brings extensive experience in product development, commercialization, and strategic partnerships. During his tenure as US President of Merck, he oversaw commercial teams across a dozen therapeutic areas, managing over $12 billion in revenue. Prior to that role, he served as Managing Director for Merck\u2019s Australian and New Zealand operations. Mr. El-Dada\u2019s … <\/p>\n

Continue reading “Former Merck USA President Joins Klotho Neurosciences\u2019 Board of Directors”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-792055","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nFormer Merck USA President Joins Klotho Neurosciences\u2019 Board of Directors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/former-merck-usa-president-joins-klotho-neurosciences-board-of-directors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Former Merck USA President Joins Klotho Neurosciences\u2019 Board of Directors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Highly Accomplished Pharmaceutical Leader, Riad El-Dada, Further Enhances Board Expertise NEW YORK, Dec. 03, 2024 (GLOBE NEWSWIRE) — Klotho Neurosciences, Inc. (NASDAQ: KLTO), a U.S.-based biotechnology company pioneering cell and gene therapies for neurodegenerative and age-related disorders, including ALS, Alzheimer\u2019s, and Parkinson\u2019s, today announced the appointment of Riad El-Dada, former US President of Merck, to its Board of Directors. With decades of leadership in the pharmaceutical industry, Mr. El-Dada brings extensive experience in product development, commercialization, and strategic partnerships. During his tenure as US President of Merck, he oversaw commercial teams across a dozen therapeutic areas, managing over $12 billion in revenue. Prior to that role, he served as Managing Director for Merck\u2019s Australian and New Zealand operations. Mr. El-Dada\u2019s … Continue reading "Former Merck USA President Joins Klotho Neurosciences\u2019 Board of Directors"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/former-merck-usa-president-joins-klotho-neurosciences-board-of-directors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-03T16:03:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxMzIzOCM2NjIwMjgwIzUwMDEyODUzNw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/former-merck-usa-president-joins-klotho-neurosciences-board-of-directors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/former-merck-usa-president-joins-klotho-neurosciences-board-of-directors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Former Merck USA President Joins Klotho Neurosciences\u2019 Board of Directors\",\"datePublished\":\"2024-12-03T16:03:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/former-merck-usa-president-joins-klotho-neurosciences-board-of-directors\\\/\"},\"wordCount\":798,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/former-merck-usa-president-joins-klotho-neurosciences-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxMzIzOCM2NjIwMjgwIzUwMDEyODUzNw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/former-merck-usa-president-joins-klotho-neurosciences-board-of-directors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/former-merck-usa-president-joins-klotho-neurosciences-board-of-directors\\\/\",\"name\":\"Former Merck USA President Joins Klotho Neurosciences\u2019 Board of Directors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/former-merck-usa-president-joins-klotho-neurosciences-board-of-directors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/former-merck-usa-president-joins-klotho-neurosciences-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxMzIzOCM2NjIwMjgwIzUwMDEyODUzNw==\",\"datePublished\":\"2024-12-03T16:03:57+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/former-merck-usa-president-joins-klotho-neurosciences-board-of-directors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/former-merck-usa-president-joins-klotho-neurosciences-board-of-directors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/former-merck-usa-president-joins-klotho-neurosciences-board-of-directors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxMzIzOCM2NjIwMjgwIzUwMDEyODUzNw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxMzIzOCM2NjIwMjgwIzUwMDEyODUzNw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/former-merck-usa-president-joins-klotho-neurosciences-board-of-directors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Former Merck USA President Joins Klotho Neurosciences\u2019 Board of Directors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Former Merck USA President Joins Klotho Neurosciences\u2019 Board of Directors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/former-merck-usa-president-joins-klotho-neurosciences-board-of-directors\/","og_locale":"en_US","og_type":"article","og_title":"Former Merck USA President Joins Klotho Neurosciences\u2019 Board of Directors - Market Newsdesk","og_description":"Highly Accomplished Pharmaceutical Leader, Riad El-Dada, Further Enhances Board Expertise NEW YORK, Dec. 03, 2024 (GLOBE NEWSWIRE) — Klotho Neurosciences, Inc. (NASDAQ: KLTO), a U.S.-based biotechnology company pioneering cell and gene therapies for neurodegenerative and age-related disorders, including ALS, Alzheimer\u2019s, and Parkinson\u2019s, today announced the appointment of Riad El-Dada, former US President of Merck, to its Board of Directors. With decades of leadership in the pharmaceutical industry, Mr. El-Dada brings extensive experience in product development, commercialization, and strategic partnerships. During his tenure as US President of Merck, he oversaw commercial teams across a dozen therapeutic areas, managing over $12 billion in revenue. Prior to that role, he served as Managing Director for Merck\u2019s Australian and New Zealand operations. Mr. El-Dada\u2019s … Continue reading \"Former Merck USA President Joins Klotho Neurosciences\u2019 Board of Directors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/former-merck-usa-president-joins-klotho-neurosciences-board-of-directors\/","og_site_name":"Market Newsdesk","article_published_time":"2024-12-03T16:03:57+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxMzIzOCM2NjIwMjgwIzUwMDEyODUzNw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/former-merck-usa-president-joins-klotho-neurosciences-board-of-directors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/former-merck-usa-president-joins-klotho-neurosciences-board-of-directors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Former Merck USA President Joins Klotho Neurosciences\u2019 Board of Directors","datePublished":"2024-12-03T16:03:57+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/former-merck-usa-president-joins-klotho-neurosciences-board-of-directors\/"},"wordCount":798,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/former-merck-usa-president-joins-klotho-neurosciences-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxMzIzOCM2NjIwMjgwIzUwMDEyODUzNw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/former-merck-usa-president-joins-klotho-neurosciences-board-of-directors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/former-merck-usa-president-joins-klotho-neurosciences-board-of-directors\/","name":"Former Merck USA President Joins Klotho Neurosciences\u2019 Board of Directors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/former-merck-usa-president-joins-klotho-neurosciences-board-of-directors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/former-merck-usa-president-joins-klotho-neurosciences-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxMzIzOCM2NjIwMjgwIzUwMDEyODUzNw==","datePublished":"2024-12-03T16:03:57+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/former-merck-usa-president-joins-klotho-neurosciences-board-of-directors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/former-merck-usa-president-joins-klotho-neurosciences-board-of-directors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/former-merck-usa-president-joins-klotho-neurosciences-board-of-directors\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxMzIzOCM2NjIwMjgwIzUwMDEyODUzNw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxMzIzOCM2NjIwMjgwIzUwMDEyODUzNw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/former-merck-usa-president-joins-klotho-neurosciences-board-of-directors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Former Merck USA President Joins Klotho Neurosciences\u2019 Board of Directors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/792055","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=792055"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/792055\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=792055"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=792055"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=792055"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}